Anti-apoptosis mechanisms in malignant gliomas

Journal of Clinical Oncology

Volumn 26, Issue 3, 2008, Pages 493-500

  Ziegler, David S ^a   Kung, Andrew L ^a   Kieran, Mark W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 PROPOXYMETHYL MALEIMIDE; 4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; CARMUSTINE; CHEMOKINE RECEPTOR CXCR4; DEATH RECEPTOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; IAP INHIBITOR; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MAPATUMUMAB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLERIXAFOR; PRIMA 1; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN INHIBITOR; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; STROMAL CELL DERIVED FACTOR 1; TEMOZOLOMIDE; TEMSIROLIMUS; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GLIOBLASTOMA; HUMAN; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; GLIOMA; HUMANS;

EID: 38649132548     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.9717     Document Type: Review

References (91)

1. DeAngelis LM: Brain tumors. N Engl J Med 344:114-123, 2001
2. Reardon DA, Rich JN, Friedman HS, et al: Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 24:1253-1265, 2006
3. Medical Research Council Brain Tumor Working Party: Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council trial. J Clin Oncol 19:509-518, 2001
4. Athanassiou H, Synodinou M, Maragoudakis E, et al: Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 23:2372-2377, 2005
5. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
6. Degterev A, Boyce M, Yuan J: A decade of caspases. Oncogene 22:8543-8567, 2003
7. Debatin K-M: Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 53:153-159, 2004
8. Schmitt CA: Senescence, apoptosis and therapy: Cutting the lifelines of cancer. Nat Rev Cancer 3:286-295, 2003
9. Klein S, McCormick F, Levitzki A: Killing time for cancer cells. Nat Rev Cancer 5:573-580, 2005
10. Danial NN, Korsmeyer SJ: Cell death: Critical control points. Cell 116:205-219, 2004
11. O'Neill J, Manion M, Schwartz P, et al: Promises and challenges of targeting Bcl-2 anti-apoptotic proteins for cancer therapy. Biochim Biophys Acta 1705:43-51, 2004
12. Rieger J, Naumann U, Glaser T, et al: APO2 ligand: A novel lethal weapon against malignant glioma? FEBS Lett 427:124-128, 1998
13. Frank S, Kohler U, Schackert G, et al: Expression of TRAIL and its receptors in human brain tumors. Biochem Biophys Res Commun 257:454-459, 1999
14. Kuijlen JM, Mooij JJ, Platteel I, et al: TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. J Neurooncol 78:161-171, 2006
15. Hao C, Beguinot F, Condorelli G, et al: Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apoptosis in human malignant glioma cells. Cancer Res 61:1162-1170, 2001
16. Nagane M, Pan G, Weddle JJ, et al: Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 60:847-853, 2000
17. Saito R, Bringas JR, Panner A, et al: Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res 64:6858-6862, 2004
18. Puduvalli VK, Sampath D, Bruner JM, et al: TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis 10:233-243, 2005
19. Koschny R, Holland H, Sykora J, et al: Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res 13:3403-3412, 2007
20. Sonnemann J, Kumar KS, Heesch S, et al: Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int J Oncol 28:755-766, 2006
21. Panner A, James CD, Berger MS, et al: mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 25:8809-8823, 2005
22. Jo M, Kim TH, Seol DW, et al: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6:564-567, 2000
23. Lawrence D, Shahrokh Z, Marsters S, et al: Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7:383-385, 2001
24. Tolcher AW, Mita M, Meropol NJ, et al: Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 25:1390-1395, 2007
25. Steinbach JP, Weller M: Apoptosis in gliomas: Molecular mechanisms and therapeutic implications. J Neurooncol 70:247-256, 2004
26. McDonald FE, Ironside JW, Gregor A, et al: The prognostic influence of bcl-2 in malignant glioma. Br J Cancer 86:1899-1904, 2002
27. Stegh AH, Kim H, Bachoo RM, et al: Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 21:98-111, 2007
28. Jiang Z, Zheng X, Rich KM: Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death. J Neurochem 84:273-281, 2003
29. Zhu CJ, Li YB, Wong MC: Expression of antisense bcl-2 cDNA abolishes tumorigenicity and enhances chemosensitivity of human malignant glioma cells. J Neurosci Res 74:60-66, 2003
30. Guensberg P, Wacheck V, Lucas T, et al: Bcl-xL antisense oligonucleotides chemosensitize human glioblastoma cells. Chemotherapy 48:189-195, 2002
31. Bedikian AY, Millward M, Pehamberger H, et al: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J Clin Oncol 24:4738-4745, 2006
32. Walensky LD, Kung AL, Escher I, et al: Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305:1466-1470, 2004
33. Manero F, Gautier F, Gallenne T, et al: The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res 66:2757-2764, 2006
34. Oltersdorf T, Elmore SW, Shoemaker AR, et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-681, 2005
35. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A: Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 117:112-121, 2007
36. Kang MH, Kang YH, Szymanska B, et al: Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 110:2057-2066, 2007
37. Kline MP, Rajkumar SV, Timm MM, et al: ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 21:1549-1560, 2007
38. Kohl TM, Hellinger C, Ahmed F, et al: BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia 21:1763-1772, 2007
39. Konopleva M, Contractor R, Tsao T, et al: Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10:375-388, 2006
40. Trudel S, Stewart AK, Li Z, et al: The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 13:621-629, 2007
41. Wagenknecht B, Glaser T, Naumann U, et al: Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma. Cell Death Differ 6:370-376, 1999
42. Chen Z, Naito M, Hori S, et al: A human IAP-family gene, apollon, expressed in human brain cancer cells. Biochem Biophys Res Commun 264:847-854, 1999
43. Chakravarti A, Noll E, Black PM, et al: Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 20:1063-1068, 2002
44. Chakravarti A, Zhai GG, Zhang M, et al: Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 23:7494-7506, 2004
45. Zhen HN, Zhang X, Hu PZ, et al: Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Cancer 104:2775-2783, 2005
46. Fulda S, Wick W, Weller M, et al: Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8:808-815, 2002
47. Giagkousiklidis S, Vogler M, Westhoff MA, et al: Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. Cancer Res 65:10502-10513, 2005
48. Li L, Thomas RM, Suzuki H, et al: A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 305:1471-1474, 2004
49. Naumann U, Bahr O, Wolburg H, et al: Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice. Gene Ther 14:147-161, 2007
50. Letai A: Growth factor withdrawal and apoptosis: The middle game. Mol Cell 21:728-730, 2006
51. Broniscer A, Gajjar A: Supratentorial high-grade astrocytoma and diffuse brainstem glioma: Two challenges for the pediatric oncologist. Oncologist 9:197-206, 2004
52. Mellinghoff IK, Wang MY, Vivanco I, et al: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012-2024, 2005
53. Bögler O, Mikkelsen T: Angiogenesis and apoptosis in glioma: Two arenas for promising new therapies. J Cell Biochem 96:16-24, 2005
54. Nagane M, Levitzki A, Gazit A, et al: Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A 95:5724-5729, 1998
55. Nagane M, Coufal F, Lin H, et al: A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56:5079-5086, 1996
56. Mishima K, Johns TG, Luwor RB, et al: Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 61:5349-5354, 2001
57. Raizer JJ, Malkin MG, Kleber M, et al: Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. Neuro-oncology 6:247-252, 2004
58. Rich JN, Reardon DA, Peery T, et al: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133-142, 2004
59. Van Den Bent MJ, Brandes A, Rampling R, et al: Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034. J Clin Oncol 25:76s, 2007 (suppl; abstr 2005)
60. Haas-Kogan DA, Prados MD, Tihan T, et al: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97:880-887, 2005
61. Fleming TP, Saxena A, Clark WC, et al: Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52:4550-4553, 1992
62. Hermanson M, Funa K, Hartman M, et al: Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52:3213-3219, 1992
63. Guha A, Dashner K, Black PM, et al: Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer 60:168-173, 1995
64. Kesari S, Ramakrishna N, Sauvageot C, et al: Targeted molecular therapy of malignant gliomas. Curr Oncol Rep 8:58-70, 2006
65. Kilic T, Alberta JA, Zdunek PR, et al: Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 60:5143-5150, 2000
66. Holdhoff M, Kreuzer KA, Appelt C, et al: Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 34:181-185, 2005
67. Wen PY, Yung WK, Lamborn KR, et al: Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12:4899-4907, 2006
68. Reardon DA, Egorin MJ, Quinn JA, et al: Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23:9359-9368, 2005
69. Matei D, Chang DD, Jeng MH: Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res 10(2):681-690, 2004
70. Zou YR, Kottmann AH, Kuroda M, et al: Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393:595-599, 1998
71. Rubin JB, Kung AL, Klein RS, et al: A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A 100:13513-13518, 2003
72. Hendrix CW, Flexner C, MacFarland RT, et al: Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 44:1667-1673, 2000
73. Hendrix CW, Collier AC, Lederman MM, et al: Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 37:1253-1262, 2004
74. Genzyme announces phase 3 trial of mozobil in non-hodgkin's lymphoma meets primary endpoint. http://www.genzyme.com/corp/investors/GENZ%20PR-071907. asp
75. Redjal N, Chan JA, Segal RA, et al: CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clin Cancer Res 12:6765-6771, 2006
76. Ishii N, Maier D, Merlo A, et al: Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 9:469-479, 1999
77. Marx J: Oncology: Recruiting the cell's own guardian for cancer therapy. Science 315:1211-1213, 2007
78. Wischhusen J, Naumann U, Ohgaki H, et al: CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 22:8233-8245, 2003
79. Bykov VJ, Issaeva N, Shilov A, et al: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8:282-288, 2002
80. Bykov VJ, Issaeva N, Zache N, et al: Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 280:30384-30391, 2005
81. Vassilev LT, Vu BT, Graves B, et al: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848, 2004
82. Eshleman JS, Carlson BL, Mladek AC, et al: Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 62:7291-7297, 2002
83. Geoerger B, Kerr K, Tang CB, et al: Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 61:1527-1532, 2001
84. Goudar RK, Shi Q, Hjelmeland MD, et al: Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4:101-112, 2005
85. Rao RD, Mladek AC, Lamont JD, et al: Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia 7:921-929, 2005
86. Wang MY, Lu KV, Zhu S, et al: Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 66:7864-7869, 2006
87. Galanis E, Buckner JC, Maurer MJ, et al: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 23:5294-5304, 2005
88. Chang SM, Wen P, Cloughesy T, et al: Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23:357-361, 2005
89. Doherty L, Gigas DC, Kesari S, et al: Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67:156-158, 2006
90. Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature 432:396-401, 2004
91. Bao S, Wu Q, McLendon RE, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-760, 2006